itoba, Canada, and then licensed to NewLink Genetics Corp through its wholly owned subsidiary BioProtection Systems, both based in Ames, Iowa. Separately, Johnson & Johnson is also developing a dual-component, prime-boost candidate vaccine against the Ebola virus.
Meanwhile, the chikungunya virus is steadfastly making its way into the Americas, initially infıltrating islands in the Caribbean late in 2013, then the South American mainland and Central America a few months later, and into Florida by the middle of 2014, according to Ann Powers of the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. The Asian rather than the African genotype is the predominant strain of chikungunya virus now circulating in this hemisphere.
Among several approaches to developing vaccines to protect against chikungunya, the apparent front runner is a virus-like particle (VLP) version that entered a phase 1 clinical trial several years ago, according to Julie Ledgerwood of NIAID. Although its principal antigen derives from a West African strain of chikungunya, the antibodies this vaccine elicits are expected to be fully cross-reactive with other strains of the virus, including the Asian genotype now circulating in South and Central America, she says.
The VLP candidate vaccine elicits an "impressive" antibody response, and there is boosting after each injection, according to Ledgerwood. Unlike an older, live-attenuated candidate vaccine for chikungunya, clinical testing of the newer VLP led to virtually no side effects, and it induces neutralizing antibodies at all doses, she says. Although a clinical effıcacy trial is a logical next step, offıcials fınd themselves stymied because outbreaks tend to be sporadic, making it diffıcult to plan such a trial. Further, chikungunya and Dengue virus outbreaks intermingle, with both viruses causing nearly identical symptoms-yet another complication for those seeking to plan clinical trials for vaccines targeting either one of these viruses. Reports (doi:10.1016 Reports (doi:10. /j.celrep.2015 . This effect of tetracyclines could confound experimental outcomes, and the data suggest a potential negative impact on the environment and health that should be further explored, they point out.
More generally, antibiotic-induced changes in the gut can be explained by three factors, the researchers note: depletion of the microbiota, direct effects of antibiotics on host tissues, and the effects of remaining antibiotic-resistant microbes, according to Morgun. "Our most surprising fınding was that antibiotic-resistant bacteria and the antibiotics themselves caused many of the same toxicities," he says.
Although antibiotics reduce immune responses in the gut, whether that damage is direct, mediated through the microbiome, or from
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Microbiology Policy Bulletin Board
Recent national and international developments involving microbiology and related science policy matters include:
• Officials of the Food and Drug Administration (FDA) in February approved Avycaz, a combination of ceftazidime, a cephalosporin, and avibactam, a ␤-lactamase inhibitor, to treat adults with complicated intra-abdominal infections (in combination with metronidazole) and complicated urinary tract infections. other effects was uncertain before Morgun and his collaborators compared mucosal immunity in antibiotictreated mice with that in germ-free mice, which have reduced immunity because they lack a microbiome. The antibiotic-treated mice show a similar reduction in immunity. For both sets of mice, the genes responsible for reduced immunity map to two compartments along the inner surfaces of the gastrointestinal tract, i.e.,the lamina propria and the villous epithelium. Although ordinarily copious, immune cells in these gastrointestinal compartments "disappear in the absence of microbes," the researchers note. To determine which bacteria and which of their genes repress immunity, the investigators analyzed what they call "trans-kingdom networks." This new method involves correlating microbes and their genes with host behaviors to model host-microbe interactions. Just as a sheep influences the behavior of a nearby sheepdog, a particular microbe might influence expression of specifıc host genes, says Morgun's collaborator and former mentor, Polly Matzinger of the National Institute of Allergy and Infectious Diseases in Bethesda, Md., in whose lab this research began.
For instance, following antibiotic treatment, the gut population of Pseudomonas aeruginosa expands as commensal bacteria are depleted and as immunity declines, leading to death of gut epithelial cells, according to Morgun, Shulzhenko, and their collaborators. Because P. aeruginosa bacteria carry genes encoding enzymes that can produce cyanide, the rising numbers and density of these bacterial cells produce higher amounts of cyanide while also activating "quorum-sensing-controlled virulence factors," they note. "The virulence factors, including the cyanide, directly stimulate mitochondria-dependent apoptosis in the intestinal epithelium." As with antibiotics, the virulence factors also interfere with mitochondrial respiration and damage mitochondrial ribosomes.
These fındings eventually could help to "design antibiotics that will reduce the harm to good bacteria and to host metabolism," says Andrew Gewirtz of Georgia State University in Atlanta. "This should help avoid the secondary infections and adverse effects that can result from antibiotics."
David C. Holzman is the Microbe Journal Highlights Editor.
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Fungi-the Bad, the Good, and the Complicated
Recent developments involving fungi portray them playing a range of positive and negative roles, including:
• The fungus Mycosphaerella populorum produces a toxin that can cause fatal lesions on poplar trees, according to • Up to 40% of the symbiosis-induced genes from ectomycorrhizal fungi-which emerged less than 200 million years ago-are restricted to a single species, and such lineages undergo huge turnovers of those genes that are upregulated in symbiosis, suggesting that the evolution of the symbiosis is associated with "massive genetic innovation," according to Igor Grigoriev at the U.S. 
